A roundup of some of the most read news and updates in acute myeloid leukemia in 2020 from CURE®.
There have been several updates in the field of acute myeloid leukemia in 2020. Here, CURE® looks back at some of the top news and updates in this field that patients read the most.
Patients with acute myeloid leukemia (AML) often have to undergo transplant during treatment but are susceptible to other side effects, but new research indicates that the use of immunotherapy after these treatments can improve patient outcomes. READ MORE.
Patients with AML whose disease has relapsed or become resistant to treatment saw a benefit with a combination of Opdivo and Vidaza. READ MORE.
The COVID-19 pandemic has created a unique challenge for patients with myelodysplastic syndromes and AML, creating many questions that experts tried to answer in an April webinar from The Aplastic Anemia and MDS International Foundation. READ MORE.
Adding Venclexta (venetoclax) to Vidaza (azacitadine) chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed. READ MORE.
A feature in CURE®’s Hematology special issue in March analyzed a wave of new targeted therapies expanding the options in AML. READ MORE.